Speaking With Your Doctor

Sometimes it may seem hard to describe your diarrhea to your doctor. One of the best ways to let your doctor know what is happening is to track the number and type of your bowel movements. This will help your doctor know how to better help you get relief from your diarrhea. You should keep track of the number of times you have a bowel movement each day. This lets your doctor know the frequency of your stools.

Doctors also like to know the type of your stools and commonly use the Bristol Stool Chart to understand what kind of stools you are having. Click on the link below to print out your copy of the Bristol Stool Chart and take it with you to your doctor visit to let him or her know what type of stool you’re having each time you have a bowel movement.

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Please click here for full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

REFERENCES: 1. Mayo Clinic. Diarrhea causes. http://www.mayoclinic.org/diseases-conditions/diarrhea/basics/causes/con-20014025. Accessed July 8, 2016. 2. Rome Foundation. Appendix A. Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. http://www.romecriteria.org/assets/pdf/19_RomeIII_apA_885-898.pdf. Accessed July 8, 2016. 3. Motofen [package insert]. Roswell, GA: Sebela Pharmaceuticals; August 2018. 4. Data on file, Sebela Pharmaceuticals. 5. Lomotil Tablets [package insert]. New York, NY: Pfizer Inc.; 2018.

Lomotil is a registered trademark of Pfizer Inc.

Important Safety Information

INDICATIONS AND USAGE: Motofen^® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
CONTRAINDICATIONS: Motofen^® is contraindicated in patients with diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics.
Motofen^® is also contraindicated in children under 2 years of age, in patients with known hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are jaundiced.
WARNINGS AND PRECAUTIONS: Motofen^® is not an innocuous drug and dosage recommendations should be strictly adhered to. Overdose may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death.
The use of Motofen^® does not preclude the administration of appropriate fluid and electrolyte therapy. Dehydration, particularly in children, may further influence the variability of response to Motofen^® and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen^® may produce drowsiness or dizziness. Use caution when engaging in activities requiring mental alertness, such as driving or operating dangerous machinery.
Safety and effectiveness in children below the age of 12 have not been established.
Keep out of reach of children.

Please click here for full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Lomotil is a registered trademark of Pfizer Inc.